Paliperidon Teva (Paliperidone Palmitate)

Paliperidone palmitate, the active ingredient in Paliperidon Teva, is an atypical antipsychotic presented as a long‑acting injectable suspension for intramuscular use. It is indicated for the treatment of schizophrenia in adult patients. GNH USA supplies Paliperidon Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Paliperidon Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone palmitate is used in the management of chronic psychiatric conditions, primarily targeting the schizophrenia disease pathway.

- Schizophrenia: Reduces risk of relapse and stabilises symptoms in adults. - Schizoaffective disorder: Helps control mood‑related psychotic symptoms. - Maintenance therapy: Provides sustained symptom control with monthly or quarterly dosing, reducing the need for daily oral medication.

Paliperidone palmitate may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Injection site pain - Headache - Weight gain - Drowsiness - Restlessness (akathisia) - Dry mouth

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe hypotension - Seizures - Hyperglycaemia - Orthostatic falls

When prescribing Paliperidone palmitate, clinicians should consider several safety aspects.

- Cardiovascular assessment: Evaluate for history of arrhythmias or orthostatic hypotension. - Metabolic monitoring: Check glucose and lipid profiles regularly. - Pregnancy and lactation: Use only if the benefit‑to‑risk ​  "); - Elderly patients: Monitor for falls and sedation. - Drug‑interaction review: Assess  "); - Store at ambient temperature: keep in original packaging ​

Paliperidosa  

Major  

");

");

");